Veradigm vs Labcorp
Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare data company with 130K connected physicians; EHR-connected real-world evidence network for pharma analytics rebranded from Allscripts competing with IQVIA for life sciences data.
About
Veradigm (formerly Allscripts Healthcare) is a healthcare information technology company providing EHR-connected data network services, physician practice management software, pharmacy solutions, and life sciences data analytics — operating at the intersection of clinical care delivery and healthcare data commercialization. Listed on NASDAQ (NASDAQ: MDRX) and headquartered in Chicago, Illinois, Veradigm rebranded from Allscripts in 2023 as it refocused from clinical EHR software toward data and analytics services, generating approximately $600 million in annual revenue.\n\nVeradigm's core asset is its network of approximately 130,000 connected physicians and tens of millions of de-identified patient records accessible through its data products. The Veradigm Network connects ambulatory physician practices running Allscripts EHR (Professional EHR, TouchWorks) and enables data flows for prescription analytics, clinical decision support, and real-world evidence (RWE) for pharmaceutical companies. The life sciences data business provides pharma clients with prescription analytics, patient journey data, and clinical research data services.\n\nIn 2025, Veradigm is in strategic transition — the company has been exploring alternatives to maximize shareholder value, including potential sale or acquisition, following activist investor pressure. The EHR product portfolio (Allscripts-branded physician practice software) competes with athenahealth, Epic, and eClinicalWorks in the ambulatory market, though Veradigm's focus has shifted toward its data network value rather than competing head-to-head in EHR functionality. Veradigm competes with IQVIA, Komodo Health, and Definitive Healthcare for life sciences real-world data. The 2025 strategy focuses on growing the data analytics and real-world evidence business while managing the legacy EHR product base.
Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.
About
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.